Next Milestone Ventures

Cyril Eleftheriou HS

Co-Nexi Vision

Technologies

Therapeutic

Indication

Neurodegenerative Disease

Executive Summary

View/Download

Cyril Eleftheriou

Cyril has an artificial dopaminergic neuron for treating light-adaptation deficits in the retinas of patients with dystrophic retinal conditions, including night-blindness.

Newsletter Signup

Corporate Supporters

 

                                      

wbca-dashed-rule

Westchester County Biosciences Accelerator is a Program of

Initiated by